Compare GMED & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMED | MRNA |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 11.5B |
| IPO Year | 2012 | 2018 |
| Metric | GMED | MRNA |
|---|---|---|
| Price | $93.99 | $49.79 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $95.92 | $32.75 |
| AVG Volume (30 Days) | 1.5M | ★ 11.9M |
| Earning Date | 02-24-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 358.86 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $2,769,804,000.00 | $2,232,000,000.00 |
| Revenue This Year | $17.65 | N/A |
| Revenue Next Year | $8.37 | $3.18 |
| P/E Ratio | $30.18 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $51.79 | $22.28 |
| 52 Week High | $101.40 | $45.40 |
| Indicator | GMED | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 80.83 |
| Support Level | $91.10 | $39.21 |
| Resistance Level | $94.69 | $41.98 |
| Average True Range (ATR) | 3.21 | 2.65 |
| MACD | -0.03 | 1.24 |
| Stochastic Oscillator | 52.96 | 99.84 |
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.